aceThe Virtual Biotech: A multi-agent AI framework for therapeutic discovery and development
Drug development requires evidence integration across biological scales and modalities, but relevant tools are fragmented. We introduce the Virtual Biotech, an organization of artificial intelligence (AI) agents modeled on a drug-development company, with agentic divisions spanning target discovery, safety assessment, modality selection, and clinical development. We demonstrate its utility at three drug-development decision points. First, more than 37,000 agents annotated outcomes from 55,984 trials and found th…
A coordinated team of AI agents annotated tens of thousands of trial outcomes and identified that drugs aimed at cell type-specific genes were more likely to reach market with fewer adverse events.
The ulcerative colitis analysis only inferred potential mechanisms of failure, so those explanations are not confirmed causes.
Evidence
- Peer-reviewedScience2026-10-22
How should this claim be treated?
Truvace Impact Record TRV-2026-2227, v1: “The Virtual Biotech: A multi-agent AI framework for therapeutic discovery and development.” Truvace, 2026-10-24. /record/TRV-2026-2227 (accessed at citation time). sha256 d6b86f2a571c3b7c…
Calibration history
Every change to this record since certification, in the open. None yet — the reading has held since it entered the record.
Certified into the record
How to verify without trusting this page
Fetch the canonical text of any version from /api/record/TRV-2026-2227 and hash it yourself — for example shasum -a 256 on the saved canonical field. The result must equal content_hash, and each version’s text ends with prev:followed by the prior version’s hash (version 1 chains to 64 zeros). If a single character of any version had been altered since certification, the chain would not reproduce.